NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
NovoCure total assets
Total assets on the balance sheet at the end of each period.
NovoCure's total assets was $828.71M at Sep 30, 2026. For fiscal 2025 it was $804.33M, down 35.2% from the year before. Over ten years it grew 10.1% a year on average. The highest annual figure on record is $1.24B in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $804.33M | -35.2% |
| FY2024 | Dec 31, 2024 | $1.24B | +8.3% |
| FY2023 | Dec 31, 2023 | $1.15B | -3.8% |
| FY2022 | Dec 31, 2022 | $1.19B | +4.6% |
| FY2021 | Dec 31, 2021 | $1.14B | +8.3% |
| FY2020 | Dec 31, 2020 | $1.05B | +119.4% |
| FY2019 | Dec 31, 2019 | $479.45M | +41.1% |
| FY2018 | Dec 31, 2018 | $339.79M | +28.1% |
| FY2017 | Dec 31, 2017 | $265.30M | -5.9% |
| FY2016 | Dec 31, 2016 | $282.08M | -8.2% |
| FY2015 | Dec 31, 2015 | $307.34M | +160.7% |
| FY2014 | Dec 31, 2014 | $117.88M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $828.71M | -39.1% |
| Q2 FY2026 | Jun 30, 2026 | $795.19M | -36.2% |
| Q1 FY2026 | Mar 31, 2026 | $787.93M | -36.9% |
| Q4 FY2025 | Dec 31, 2025 | $804.33M | -35.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.36B | +11.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.25B | +2.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.25B | +11.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.24B | +8.3% |
| Q3 FY2024 | Sep 30, 2024 | $1.22B | +6.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.21B | +4.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.12B | -4.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.15B | -3.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.15B | -2.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.16B | -0.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.17B | +2.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.19B | +4.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.17B | +4.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.16B | +6.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.15B | +7.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.14B | +8.3% |
| Q3 FY2021 | Sep 30, 2021 | $1.12B | +159.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.10B | +107.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.07B | +112.5% |
| Q4 FY2020 | Dec 31, 2020 | $1.05B | +119.4% |
| Q3 FY2020 | Sep 30, 2020 | $431.05M | -2.9% |
| Q2 FY2020 | Jun 30, 2020 | $528.94M | +30.2% |
| Q1 FY2020 | Mar 31, 2020 | $502.45M | +35.7% |
| Q4 FY2019 | Dec 31, 2019 | $479.45M | +41.1% |
| Q3 FY2019 | Sep 30, 2019 | $443.86M | +40.7% |
| Q2 FY2019 | Jun 30, 2019 | $406.19M | +31.1% |
| Q1 FY2019 | Mar 31, 2019 | $370.26M | +22.0% |
| Q4 FY2018 | Dec 31, 2018 | $339.79M | +28.1% |
| Q3 FY2018 | Sep 30, 2018 | $315.51M | +20.3% |
| Q2 FY2018 | Jun 30, 2018 | $309.88M | +20.6% |
| Q1 FY2018 | Mar 31, 2018 | $303.48M | +14.7% |
| Q4 FY2017 | Dec 31, 2017 | $265.30M | -5.9% |
| Q3 FY2017 | Sep 30, 2017 | $262.28M | – |
| Q2 FY2017 | Jun 30, 2017 | $257.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $264.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $282.08M | – |
See a number that looks wrong?